Previous 10 | Next 10 |
Invites all Shareholders and Investors to Participate CLEVELAND, OH / ACCESSWIRE / November 8, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its annual meeting of shareholders will take pla...
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1 FDA Expands the Scope of the Company's Submission Accelerates Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CLEVELAND, OH / ACCESSWIRE / October 26, 2022 / NovAccess Global Inc. (OTCQB:XS...
Topic: Opportunities for the Biomedical Field and for Shareholders CLEVELAND, OH / ACCESSWIRE / October 20, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its initial instal...
CLEVELAND, OH / ACCESSWIRE / September 29, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that it will be conducting a series of interviews with its corporate leadership on a monthly basis for the nex...
Includes 7.5 Million Shares for Innovest Global Share Distribution Increases Unaffiliated Float While Significantly Expanding Shareholder Base CLEVELAND, OH / ACCESSWIRE / September 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies...
CLEVELAND, OH / ACCESSWIRE / August 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that the trading of its common shares has been upgraded to the OTC Markets Group's OTCQB® platform from the ...
This corrects the release that ran earlier today, replacing the name of the executive quoted in the press release and other minor edits. Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CLEVELAND, OH / ACCESSWIRE / July 19, 2022 / NovAccess Global Inc. ...
Accelerating on the Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CLEVELAND, OH / ACCESSWIRE / July 19, 2022 / NovAccess Global Inc. (OTC PINK:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the filing of an application ...
CLEVELAND, OH / ACCESSWIRE / June 14, 2022 / NovAccess Global Inc. (OTC PINK:XSNX) announced that its Chief Executive Officer Dr. Dwain Irvin was a featured guest on MoneyTV, an internationally-syndicated weekly business television program reaching more than 180 million TV households globall...
HOLLYWOOD, CA / ACCESSWIRE / June 10, 2022 / Cancer treatment, metaverse, coping; this week on MoneyTV with Donald Baillargeon MoneyTV is the internationally syndicated television program all about money and what makes it happen, ( http://www.moneytv.net ), featuring informative interviews ...
News, Short Squeeze, Breakout and More Instantly...
CLEVELAND, OH / ACCESSWIRE / May 21, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a pioneering biomedical company developing innovative immunotherapies for brain tumor patients, today announced it has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance...
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company ...
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from Cedars-Sinai Medi...